Mirimus is an established and trusted preclinical discovery partner, generating over 50 custom mouse and rat models a year for a wide range of biopharma clients that include Novartis, Roche, Genentech, Intra-Cellular Therapeutics, and Catalyst Biosciences.
Mirimus provides end-to-end custom mouse model generation, beginning with model design, cloning, genome engineering and full embryology services. Clients can tap into Mirimus’ expertise in molecular engineering, RNA interference and CRISPR/Cas9 technologies to create advanced preclinical research models that will pave the way toward our understanding of disease pathogenesis and bring us better, faster cures.
Mirimus is the only company creating RNAi rat models for rapid drug target validation. This important preclinical model species improves dose-escalation/drug toxicity studies with serial sampling and allows assessments of complex behaviors that can enhance our understanding of human diseases. The ability to model clinical disorders and to evaluate genetic and environmental stimuli in rat models increases our confidence in predicting drug responses in humans and pushes drug discovery research into a new era.
